Cited by 53Nonmelanoma Skin Cancer StudiesPhotodynamic Therapy Research StudiesSkin Protection and Aging

A Regimen to Minimize Pain during Blue Light Photodynamic Therapy of Actinic Keratoses: Bilaterally Controlled, Randomized Trial of Simultaneous versus Conventional Illumination

Open access
Kaw, Urvashi, Ilyas, Muneeb, Bullock, Taylor, Rittwage, Lisa, Riha, Margo, Vidimos, Allison, Hu, Bo, Warren, Christine B. +1 more·2020·Journal of the American Academy of Dermatology

Abstract

Background Blue light photodynamic therapy (PDT) is effective for actinic keratosis, but many patients experience stinging pain during illumination.Objective To compare a conventional regimen (1 hour of 5-aminolevulinic acid [ALA] preincubation, followed by blue light) versus a new modified regimen in which blue light is started immediately after ALA application.Methods A clinical trial with a bilaterally controlled, intrapatient study design was conducted with 23 patients. Topical 20% ALA was applied to the entire face and/or scalp. On 1 side of the body, blue light was started immediately and continued for either 30, 45, or 60 minutes (simultaneous PDT). On the contralateral side, the blue light began 1 hour after ALA application and lasted 1000 seconds (conventional PDT). Pain was evaluated on a scale from 0 to 10. Actinic keratosis lesion counts were determined by clinical examination and photography.Results All patients experienced significantly less pain during simultaneous illumination than during the conventional regimen. At 3 months after treatment, lesion clearance was nearly identical on the 2 sides, as determined by statistical testing of noninferiority ± 15% margin.Limitations Although bilaterally controlled, the study was relatively small. Additional studies are recommended.Conclusion The modified PDT regimen is essentially painless, yet it provides treatment efficacy similar to a conventional regimen.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaad.2019.09.010

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Blue light illumination immediately after ALA application results in significantly less pain, without losing much efficacy evaluated at 3 months after treatment, than the conventional protocol where ALA is applied hours before light treatment.

    “Furthermore, blue light illumination immediately after ALA application results in significantly less pain, without losing much efficacy evaluated at 3 months after treatment, than the conventional protocol where ALA is applied hours before light treatment [64].”

    From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [64]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 23 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Kaw, U., Ilyas, M., Bullock, T., Rittwage, L., Riha, M., Vidimos, A., Hu, B., Warren, C. B., & Maytin, E. V.
Affiliations
Cleveland Clinic (US)
Corresponding author
Maytin, Edward V.
Venue
Journal of the American Academy of Dermatology
Publisher
Elsevier BV
Published
2020-04
Volume
82
Issue
4
Pages
862-868
ISSN
0190-9622 (ISSN-L)
OpenAlex
W2972986938
Cited by
53
References
23
Citations by year
2026: 4 · 2025: 10 · 2024: 9 · 2023: 13 · 2022: 8 · 2021: 3 · 2020: 6
FWCI
3.23
Type
journal article
Language
en
Open access
Locations
  • Journal of the American Academy of Dermatology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Sun Pharma
  • National Institutes of Health
Topics
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Dermatology › Skin Protection and Aging
Keywords
actinic keratosis, 5-aminolevulinic acid, lesion clearance, non-inferiority
MeSH terms
Aged, Aged, 80 and over, Aminolevulinic Acid, Drug Administration Schedule, Facial Dermatoses, Female, Humans, Male, Middle Aged, Pain, Photochemotherapy, Scalp Dermatoses, Treatment Outcome, Photosensitizing Agents, Keratosis, Actinic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review